Arcutis and Padagis Agree to Stay Patent Lawsuit

Core Viewpoint - Arcutis Biotherapeutics has agreed to a joint stipulation to stay ongoing patent litigation with Padagis, preserving its intellectual property rights and the Hatch-Waxman stay for its product ZORYVE [1][2][3] Group 1: Patent Litigation and Agreement - Padagis has requested a stay in the patent litigation against Arcutis, which the company has agreed to, leading to the vacating of all trial dates [1] - The joint stipulation requires Padagis to inform Arcutis of any FDA correspondence regarding their ANDA for a generic version of ZORYVE [2] - The Hatch-Waxman stay of regulatory approval will be extended by one day for each day the litigation is stayed, ensuring Arcutis retains its benefits under the Act [2] Group 2: Product Information and Market Position - ZORYVE cream 0.3% is indicated for the treatment of plaque psoriasis in patients aged 6 and older, with patent protection extending until at least 2037 [3][5] - The company aims to enhance the adoption of ZORYVE as a safe alternative to steroids for treating inflammatory dermatoses [3] - Arcutis has a growing portfolio of FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [4]